Meeting
2014 ASCO Annual Meeting
A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR): Thoracic Oncology Research Group (TORG) 0911.
Authors
Yoshiro Nakahara
Department of Thoracic Oncology and Respiratory Medecine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
Yoshiro Nakahara , Yukio Hosomi , Kazuhiko Yamada , Hiroaki Okamoto , Terufumi Kato , Yuko Komase , Masanori Nishikawa , Satoshi Morita , Hideo Kunitoh , Koshiro Watanabe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
#000003313
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8080)
DOI
10.1200/jco.2014.32.15_suppl.8080
Abstract #
8080
Poster Bd #
261
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2023 ASCO Annual Meeting
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.
First Author: Charu Aggarwal
Poster
2018 ASCO Annual Meeting
Pilot trial of epidermal growth factor (EGF) ointment for the patients with epidermal growth factor receptor (EGFR) inhibitor related skin side effects.
First Author: Sung Yong Oh
Poster
2017 ASCO Annual Meeting
Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study).
First Author: Akito Hata